Lakefront Biotherapeutics (GLPGF) EPS (Diluted) Growth (1y) (2015 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) EPS (Diluted) Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 64.94% |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | -640.40% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 8.02% |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | -4.52% |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 89.89% |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 7.59% |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 315.14% |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | -84.85% |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -128.49% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -128.49% |
| Mar 31, 2026 | 110.51% |
| Dec 31, 2025 | 372.83% |
| Sep 30, 2025 | -447.71% |
| Jun 30, 2025 | 207.67% |
| Mar 31, 2025 | -264.73% |
| Dec 31, 2024 | -65.24% |
| Sep 30, 2024 | -200.38% |
| Jun 30, 2024 | 8,922.25% |
| Mar 31, 2024 | 292.08% |
| Dec 31, 2023 | 97,115.05% |
| Sep 30, 2023 | -424.79% |
| Jun 30, 2023 | 106.23% |
| Mar 31, 2023 | 433.32% |
| Dec 31, 2022 | 841.99% |
| Sep 30, 2022 | 106.16% |
| Jun 30, 2022 | 86.52% |
| Mar 31, 2022 | -165.51% |
| Dec 31, 2021 | 84.90% |
| Sep 30, 2021 | 15.15% |